A Phase 2 Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519291-11-00

Acronym

M25-191

Enrollment

Registered

2025-06-25

Start date

2025-07-25

Completion date

Unknown

Last updated

2025-11-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriatic Arthritis

Brief summary

Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 16

Detailed description

Percentage of Participants Achieving Minimal Disease Activity (MDA) Response at Week 16, Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16, Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 16, Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Response at Week 16 (in the subset of participants with a PsO BSA ≥ 3% at Baseline)

Interventions

DRUGABBV-066

DRUGLutikizumab

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response at Week 16	—

Secondary

Measure	Time frame
Percentage of Participants Achieving Minimal Disease Activity (MDA) Response at Week 16, Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16, Percentage of Participants With an American College of Rheumatology 70% (ACR70) Response at Week 16, Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Response at Week 16 (in the subset of participants with a PsO BSA ≥ 3% at Baseline)	—

Measure

Time frame

—

Countries

Czechia, France, Hungary, Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026